tradingkey.logo
tradingkey.logo

Radella Pharmaceuticals Announces New Obesity Trial Data Showing Statistically Significant Weight Loss And Broader Cardiometabolic Benefits

ReutersJul 31, 2025 1:40 PM

-

  • RADELLA PHARMACEUTICALS ANNOUNCES NEW OBESITY TRIAL DATA SHOWING STATISTICALLY SIGNIFICANT WEIGHT LOSS AND BROADER CARDIOMETABOLIC BENEFITS

  • RADELLA PHARMACEUTICALS: PHASE 1B CLINICAL TRIAL OF MD-18 TARGETING OBESITY AND TYPE 2 DIABETES MET ITS OBJECTIVES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI